Gilead HIV drug not entitled to SPC, says UK court
The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate (SPC) because it failed to meet the standards set out by Europe’s highest court earlier this year.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 August 2018 A non-profit called AIDS Healthcare Foundation has filed a petition for certiorari with the US Supreme Court in a patent dispute with Gilead.
23 August 2018 A non-profit called AIDS Healthcare Foundation has filed a petition for certiorari with the US Supreme Court in a patent dispute with Gilead.
23 August 2018 A non-profit called AIDS Healthcare Foundation has filed a petition for certiorari with the US Supreme Court in a patent dispute with Gilead.